A review of anti-D treatment of childhood idiopathic thrombocytopenic purpura.
Treatment of childhood idiopathic thrombocytopenic purpura is still an area of controversy. We reviewed the literature on anti-D treatment. Most studies used intravenous anti-D. Single doses of 50 microg/kg increased the platelet count to >or=20x10(9)/L in 70% of the children within 3 days. Intravenous anti-D seems safe in classic childhood ITP although hemolysis and occasionally renal failure may be of concern. A few studies reported intramuscularly or subcutaneously administered anti-D. Further studies on the optimal dose and route of administration of anti-D are warranted.
Kjaersgaard
Mimi
M
Department of Pediatrics, Aarhus University, Skejby Hospital, Denmark. mimi.kjaersgaard@ki.au.dk
Hasle
Henrik
H
D002648:Child; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007518:Isoantibodies / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000175:diagnosis / Q000188:drug therapy*; D018029:Rho(D) Immune Globulin
D007518:Isoantibodies; C061961:RHO(D) antibody; D018029:Rho(D) Immune Globulin